Psilocybe mushrooms, psilocybin & psilocin



Jump to:


Page 5



Page 5

Turton, Nutt & Carhart-Harris (2014). A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment. Current Drug Abuse Reviews.

Tylš, Páleníček & Horáček (2014). Psilocybin—Summary of knowledge and new perspectives. European Neuropsychopharmacology.

Wilcox (2014). Psilocybin and obsessive compulsive disorder. Journal of Psychoactive Drugs. 

Barrett, Johnson & Griffiths (2015). Validation of the revised mystical experiences questionnaire in experimental sessions with psilocybin. Drug and Alcohol Dependence.

Bogenschutz et al. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology.

Borovička et al. (2015). Phylogenetic and chemical studies in the potential psychotropic species complex of Psilocybe atrobrunnea with taxonomic and nomenclatural notes. Persoonia.

Carbonaro et al. (2015). Comparative phenomenology of psilocybin experiences in research and non-research settings. Drug and Alcohol Dependence.

Dydak et al. (2015). [Psilocybin - public available psychodysleptic]. Postepy Higieny I Medycyny Doswiadczalnej.

Gallimore (2015). Restructuring consciousness—The psychedelic state in light of integrated information theory. Frontiers in Human Neuroscience.

Garcia-Romeu, Griffiths & Johnson (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews.

Garcia-Romeu et al. (2015). Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts. Drug and Alcohol Dependence.

Gartz & Wiedemann (2015). Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov. Drug Testing and Analysis.

Geyer (2015). Lysergic Acid Diethylamide and Psilocybin Revisited. Biological Psychiatry.

Hendricks, Johnson & Griffiths (2015). Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology.

Kometer et al. (2015). Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology

Kraehenmann et al. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry.

Kraehenmann et al. (2015). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clinical.

Lebedev et al. (2015). Finding the self by losing the self: Neural correlates of ego‐dissolution under psilocybin. Human Brain Mapping.

Martin et al. (2015). Analysis of psilocin, bufotenine and LSD in hair. Journal of Analytical Toxicology.

Sakashita et al. (2015). Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biological & Pharmaceutical Bulletin.

Schindler et al. (2015). Indoleamine hallucinogens in cluster headache: results of the clusterbusters medication use survey. Journal of Psychoactive Drugs.

Spain et al. (2015). Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor agonist psilocin in the rat brain. Neuropharmacology.

Tittarelli et al. (2015). Recreational use, analysis and toxicity of tryptamines. Current Neuropharmacology.

Zhuk et al. (2015). Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice.

Barrett et al. (2016). The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology.

Breckenridge & Grobbee (2016). Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. Journal of Psychopharmacology.

Carbonaro et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology.

Carhart-Harris (2016). "Question-based Drug Development for psilocybin": Authors' reply. The Lancet Psychiatry.

Carhart-Harris (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry.

Cowen (2016). Altered states: Psilocybin for treatment-resistant depression. The Lancet Psychiatry.

Davenport (2016). Psychedelic and nonpsychedelic LSD and psilocybin for cluster headache. CMAJ.

Dijkstra, Jacobs & Cohen (2016). Question-based drug development for psilocybin. The Lancet Psychiatry.

Dos Santos et al. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology.

Gambaro et al. (2016). DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in "grow-kits" seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin. Journal of Pharmaceutical and Biomedical Analysis.

Goodwin (2016). Psilocybin: Psychotherapy or drug? Journal of Psychopharmacology.

Griffiths et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology.

Hawkes (2016). Sixty seconds on . . . psilocybin. BMJ.

Hendrie & Pickles (2016). Psilocybin: panacea or placebo? The Lancet Psychiatry.

Kelmendi et al. (2016). The role of psychedelics in palliative care reconsidered: A case for psilocybin. Journal of Psychopharmacology.

McCorvy, Olsen & Roth (2016). Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology.

Mithoefer, Grob & Brewerton (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry.

Nutt (2016). Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology.

Patra (2016). Return of the psychedelics: Psilocybin for treatment resistant depression. Asian Journal of Psychiatry.

Pokorny et al. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry.

Preller et al. (2016). Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. PNAS.

Ross et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology.

Shebloski & Broadway (2016). Commentary: Effects of psilocybin on time perception and temporal control of behavior in humans. Frontiers in Psychology.

Shelton & Hendricks (2016). Psilocybin and palliative end-of-life care. Journal of Psychopharmacology.

Spiegel (2016). Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip. Journal of Psychopharmacology.

Summergrad (2016). Psilocybin in end of life care: Implications for further research. Journal of Psychopharmacology.

Suzuki (2016). [Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning]. Chudoku Kenkyu.

Tylš et al. (2016). Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. Behavioural Pharmacology.

Barrett, Johnson & Griffiths (2017). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences.

Belser et al. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. Journal of Humanistic Psychology.